为了提高早期疾病检测的准确性和可靠性，特别是在恶性肿瘤中，对多靶点生物标志物进行详尽的研究至关重要。在这项研究中，构建了一种具有卓越性能的先进集成电化学生物传感器阵列。该生物传感器是通过可控的多孔尺寸机制和碳纳米管 (CNT) 的原位修饰而开发的，可量化多重生物标志物，特别是 C 反应蛋白 (CRP)、碳水化合物抗原 125 (CA125) 和癌胚抗原 (CEA) - 人血清血浆中。制造过程涉及通过基于微滴的微流体、纳米粒子的有限空间自组装和化学湿法蚀刻，用碳纳米管（pCNT）改性剂创建高度有序的三维反蛋白石结构。这种创新方法允许在电极阵列表面直接对纳米材料进行原位修饰，消除二次转移并提供对结构和稳定性的特殊控制。优异的电化学性能是通过pCNTs纳米材料、适配体和辣根过氧化物酶标记（HRP-）抗体的协同作用实现的。此外，集成生物传感器阵列平台包含多个可单独寻址的电极单元（n = 11），可同时进行多并行/目标测试，从而确保准确性和高通量。至关重要的是，这种集成生物传感器阵列可以准确量化人血清中的多重生物标志物，产生与商业方法相当的结果。这种集成技术有望在早期疾病诊断和生物分析中实现即时检测 (POCT)。版权所有 © 2024 Elsevier B.V. 保留所有权利。

To enhance the precision and reliability of early disease detection, especially in malignancies, an exhaustive investigation of multi-target biomarkers is essential. In this study, an advanced integrated electrochemical biosensor array that demonstrates exceptional performance was constructed. This biosensor was developed through a controllable porous-size mechanism and in-situ modification of carbon nanotubes (CNTs) to quantify multiplex biomarkers-specifically, C-reaction protein (CRP), carbohydrate antigen 125 (CA125), and carcinoembryonic antigen (CEA)-in human serum plasma. The fabrication process involved creating a highly ordered three-dimensional inverse-opal structure with the CNTs (pCNTs) modifier through microdroplet-based microfluidics, confined spatial self-assembly of nanoparticles, and chemical wet-etching. This innovative approach allowed for direct in-situ modification of nanomaterial onto the surface of electrode array, eliminating secondary transfer and providing exceptional control over structure and stability. The outstanding electrochemical performance was achieved through the synergistic effect of the pCNTs nanomaterial, aptamer, and horseradish peroxidase-labeled (HRP-) antibody. Additionally, the integrated biosensor array platform comprised multiple individually addressable electrode units (n = 11), enabling simultaneous multi-parallel/target testing, thereby ensuring accuracy and high throughput. Crucially, this integrated biosensor array accurately quantified multiplex biomarkers in human serum, yielding results comparable to commercial methods. This integrated technology holds promise for point-of-care testing (POCT) in early disease diagnosis and biological analysis.Copyright © 2024 Elsevier B.V. All rights reserved.